IGF1R and sarcoma: However, IGF-1R inhibitors have failed in clinical trials due to the complex interactions of IGF-1R with adhesion receptors and the tumor microenvironment, as well as the insufficient understanding of its role in tumor-associated immune and stromal cells [187,188], although some early-phase trials showed evidence of response, particularly in sarcomas [189].